| KIF5A — Kinesin Family Member 5A | |
|---|---|
| Symbol | KIF5A |
| Full Name | Kinesin Family Member 5A |
| Chromosome | 12q13.3 |
| NCBI Gene | 3790 |
| Ensembl | ENSG00000130224 |
| OMIM | 176602 |
| UniProt | P33175 |
| Diseases | Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Charcot-Marie-Tooth Disease |
| Expression | Neurons (CNS and PNS), particularly in axons |
Kif5A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KIF5A (Kinesin Family Member 5A) is a gene located on chromosome 12q13.3 that encodes a neuronal-specific kinesin motor protein essential for axonal transport 1. The gene is catalogued as NCBI Gene ID 3790 and OMIM 176602. KIF5A is expressed predominantly in neurons of the central and peripheral nervous systems, where it mediates anterograde transport of cargo along microtubules from the cell body to synaptic terminals 2.
KIF5A is a member of the kinesin-1 family of motor proteins, which use the energy from ATP hydrolysis to walk along microtubule tracks, transporting various cargo including synaptic vesicles, mitochondria, protein complexes, and RNA granules. Mutations in KIF5A have been linked to several neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP), and Charcot-Marie-Tooth disease type 2 3.
KIF5A is a typical kinesin-1 motor protein consisting of several functional domains:
Motor Domain (N-terminal): The globular motor domain (~350 amino acids) contains the microtubule binding site and ATPase activity. This domain hydrolyzes ATP to generate force for movement along microtubules 4.
Coiled-coil Stalk Domain: The stalk domain forms a coiled-coil structure that mediates dimerization of two KIF5A heavy chains, creating the functional motor protein.
Cargo-binding Tail Domain (C-terminal): The tail domain interacts with various cargo adaptors and regulatory proteins, determining what cargo the motor transports.
Light Chain Binding Region: KIF5A associates with kinesin light chains (KLC1-4), which further mediate cargo binding and regulation.
KIF5A functions as a homodimer (KIF5A-KIF5A) or heterodimer (KIF5A-KIF5B/KIF5C) that walks processively along microtubules toward the plus end (anterograde direction). A single kinesin dimer can take hundreds of steps without detaching, making it a highly efficient transporter 5.
The motor domain binds to microtubules in a nucleotide-dependent manner:
This nucleotide-dependent binding cycle allows the motor to "walk" along the microtubule track.
KIF5A mediates transport of numerous cargoes essential for neuronal function:
| Cargo Type | Examples | Function |
|---|---|---|
| Synaptic Vesicles | Synaptophysin, SV2, VAMP | Synaptic transmission |
| Mitochondria | Mitofusin, Miro | Energy supply to synapses |
| Protein Complexes | Neurofilaments, Tau | Cytoskeletal maintenance |
| RNA Granules | Staufen, IMP1 | Local protein synthesis |
| Signaling Molecules | BDNF vesicles, JNK pathway | Signal transduction |
KIF5A activity is tightly regulated through multiple mechanisms:
Cargo Adaptors: Various adaptor proteins link specific cargo to KIF5A, including:
Post-translational Modifications: Phosphorylation of KIF5A or its cargo adaptors modulates transport efficiency. JNK-mediated phosphorylation reduces KIF5A transport of specific cargo 6.
Microtubule Tracks: KIF5A preferentially moves along stable microtubule tracks enriched in axonal shafts. Dynamic microtubules in growth cones require different motors.
Traffic Jams: Overlapping cargo populations can create "traffic jams" that may be exacerbated in disease states.
KIF5A mutations were first linked to ALS in 2018, with subsequent studies confirming its role as an ALS risk gene 3. ALS-associated mutations in KIF5A:
The mutations cluster in the motor domain and affect microtubule binding and processivity. KIF5A mutations represent approximately 1-2% of familial ALS cases 7.
Dominant KIF5A mutations cause pure HSP (SPG10), characterized by lower limb spasticity and weakness. Mutations affect the motor domain, impairing axonal transport without causing massive neurodegeneration 8.
KIF5A mutations can also cause CMT type 2, a peripheral neuropathy characterized by distal muscle weakness and sensory loss. The CMT2 phenotype is typically less severe than ALS or HSP 9.
Defects in KIF5A-mediated transport contribute to neurodegeneration through several mechanisms:
Mitochondrial Dysfunction: Impaired transport leads to mitochondrial deficiency at synaptic terminals, energy failure, and increased oxidative stress 10.
Synaptic Failure: Loss of synaptic vesicle transport disrupts neurotransmitter release and leads to synaptic degeneration.
Protein Aggregate Transport: Impaired transport of misfolded proteins and autophagosomes leads to accumulation of toxic aggregates.
Axonal Degeneration: Disruption of axonal transport is an early event in Wallerian degeneration and contributes to "dying-back" neuropathy.
KIF5A interacts with several proteins involved in neurodegenerative diseases:
KIF5A and axonal transport represent potential therapeutic targets:
The study of Kif5A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.